Late-Breaking Data and Clinician Reviews on Now FDA-cleared T2Bacteria Panel Underscore Sepsis Prevention Opportunities at ASM Microbe 2018
“The strong customer data and conclusions expressed by clinicians at ASM Microbe on T2Bacteria are encouraging and allows us to further strengthen the momentum generated by
For the first time in the U.S., the T2Bacteria pivotal clinical trial data was presented, representing a large study of over 1,400 patient samples collected across 11 hospital and hospital systems across the U.S. The investigators concluded:
- T2Bacteria demonstrated excellent accuracy, including overall sensitivity of 90% and overall average specificity of 98%.
- T2Bacteria detected 69 patient infections that were not detected by the concurrent blood culture.
- Blood culture species identification results took an average of 3 days while T2Bacteria took an average of only 5.4 hours in the clinical trial, providing results more than 2.5 days faster.
- 66% of patients in the clinical trial with a bloodstream infection confirmed by T2 and blood culture could have benefited from earlier appropriate antibiotics based on the rapid T2Bacteria result.
- T2Bacteria also had a noted advantage in detecting infected patients on antibiotics who were missed by blood culture.
“T2 panels afford clinicians the first direct from blood diagnostics for the detection of sepsis-causing pathogens,” said clinical trial investigator
A separate evaluation of T2Bacteria by clinicians at
- T2Bacteria detected 14 infections missed by a paired blood culture – but proven to be a true infection by other cultures.
- T2Bacteria identified every infection detected by blood culture of the target species (100% sensitivity).
- T2Bacteria was highly accurate in identifying samples without an infection, with 99% average specificity.
The authors concluded that the advantages of T2Bacteria over blood culture could make it a valuable tool to enable faster time to targeted antibiotic therapy and reduced use of unnecessary antibiotics.
In a late-breaker poster from
Finally, another late-breaker poster from the
About Bloodstream Infections
Treating bloodstream infections earlier may prevent progression to sepsis, one of the leading causes of death in the U.S. and the most expensive hospital-treated condition, with costs exceeding $27 billion. Sepsis claims more lives annually than breast cancer, prostate cancer, and AIDS combined and is the most prevalent and costly cause of hospital readmissions. The pathogens that cause sepsis infections are difficult to detect and can be deadly even at very small concentrations in the bloodstream. With sepsis, one hour of delayed treatment increases mortality risk by nearly 8%.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding product pipeline, anticipated product benefits, goals and strategic priorities, product expansion or opportunities, growth expectations or targets and FDA clearance, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year-ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (SEC) on March 19, 2018, and other filings the Company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, one should not assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Tom Langford, Feinstein Kean Healthcare
Matthew Clawson, W2O Group
Source: T2 Biosystems, Inc.